Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 16, 2020

SELL
$4.64 - $5.94 $59,971 - $76,774
-12,925 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$4.4 - $6.4 $1.9 Million - $2.77 Million
-432,748 Reduced 97.1%
12,925 $65,000
Q1 2020

May 15, 2020

BUY
$3.77 - $9.91 $1.68 Million - $4.42 Million
445,673 New
445,673 $2.09 Million

Others Institutions Holding ENLV

About Enlivex Therapeutics Ltd.


  • Ticker ENLV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,403,200
  • Market Cap $28.9M
  • Description
  • Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...
More about ENLV
Track This Portfolio

Track Sabby Management, LLC Portfolio

Follow Sabby Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sabby Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sabby Management, LLC with notifications on news.